BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology. 1998;28:562-567. [PMID: 9696025 DOI: 10.1002/hep.510280238] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Li JF, Liu S, Ren F, Liu M, Wu HL, Chen Y, Zou HB, Bai L, Li Y, Zheng SJ. Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study. Int J Infect Dis. 2014;27:49-53. [PMID: 25168642 DOI: 10.1016/j.ijid.2014.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
2 Conte VP. Hepatite crônica por vírus C: Parte 1. Considerações gerais. Arq Gastroenterol 2000;37:187-93. [DOI: 10.1590/s0004-28032000000300010] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
3 Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. [PMID: 16614742 DOI: 10.7150/ijms.3.47] [Cited by in Crossref: 454] [Cited by in F6Publishing: 431] [Article Influence: 28.4] [Reference Citation Analysis]
4 Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making. 2004;24:20-29. [PMID: 15005951 DOI: 10.1177/0272989x03261568] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
5 McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006;136:125-135. [PMID: 17023002 DOI: 10.1016/j.jss.2006.04.013] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
6 Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Int J Drug Policy. 2015;26:911-921. [PMID: 26298331 DOI: 10.1016/j.drugpo.2015.07.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
7 Cheng JT, Hsien C, Josh Sun H, Tong MJ. The Emerging Importance of Chronic Hepatitis C Infection in Asian Americans. Am J Gastroenterology 2006;101:2737-43. [DOI: 10.1111/j.1572-0241.2006.00831.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
8 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
9 Ghosh S, Kaplan KJ, Schrum LW, Bonkovsky HL. Cytoskeletal proteins: shaping progression of hepatitis C virus-induced liver disease. Int Rev Cell Mol Biol 2013;302:279-319. [PMID: 23351713 DOI: 10.1016/B978-0-12-407699-0.00005-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50. [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014] [Cited by in Crossref: 1497] [Cited by in F6Publishing: 1384] [Article Influence: 83.2] [Reference Citation Analysis]
11 Silverman AL, Sekhon JS, Saginaw SJ, Wiedbrauk D, Balasubramaniam M, Gordon SC. Tattoo application is not associated with an increased risk for chronic viral hepatitis. Am J Gastroenterol 2000;95:1312-5. [PMID: 10811345 DOI: 10.1111/j.1572-0241.2000.02031.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
12 McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis. 2000;2:166-185. [PMID: 11429029 DOI: 10.1034/j.1399-3062.2000.020403.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
13 Yeung LT, To T, King SM, Roberts EA. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat. 2007;14:797-805. [PMID: 17927616 DOI: 10.1111/j.1365-2893.2007.00873.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
14 Moeremans K, Warie H, Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 2006;16:17-30. [DOI: 10.1111/j.1365-3148.2006.00644.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
15 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74-S83. [PMID: 12407579 DOI: 10.1053/jhep.2002.36807] [Cited by in Crossref: 34] [Cited by in F6Publishing: 135] [Article Influence: 1.7] [Reference Citation Analysis]
16 Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004;39:90-96. [PMID: 14752827 DOI: 10.1002/hep.20030] [Cited by in Crossref: 111] [Cited by in F6Publishing: 93] [Article Influence: 6.2] [Reference Citation Analysis]
17 Maqbool MA, Imache MR, Higgs MR, Carmouse S, Pawlotsky JM, Lerat H. Regulation of hepatitis C virus replication by nuclear translocation of nonstructural 5A protein and transcriptional activation of host genes. J Virol 2013;87:5523-39. [PMID: 23468497 DOI: 10.1128/JVI.00585-12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
18 Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29:1311-1316. [PMID: 10094980 DOI: 10.1002/hep.510290424] [Cited by in Crossref: 186] [Cited by in F6Publishing: 186] [Article Influence: 8.1] [Reference Citation Analysis]
19 Rosen HR. Primer on Hepatitis C for Hospital Epidemiologists •. Infect Control Hosp Epidemiol 2000;21:229-34. [DOI: 10.1086/501752] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
20 Ydreborg M, Söderström A, Håkanson A, Alsiö Å, Arnholm B, Malmström P, Hellstrand K, Westin J, Lagging M. Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. Scandinavian Journal of Infectious Diseases 2011;43:522-7. [DOI: 10.3109/00365548.2011.562526] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
21 Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46. [PMID: 12407575 DOI: 10.1002/hep.1840360706] [Cited by in Crossref: 482] [Cited by in F6Publishing: 299] [Article Influence: 24.1] [Reference Citation Analysis]
22 Amarapurkar D. Natural history of hepatitis C virus infection. J Gastroenterol Hepatol 2000;15:E105-10. [DOI: 10.1046/j.1440-1746.2000.02110.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
23 Seeff L. Dilemma of the natural history of hepatitis C: Natural history of hepatitis C. Journal of Gastroenterology and Hepatology 1999;14:199-201. [DOI: 10.1046/j.1440-1746.1999.01837.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
24 Hajiani E, Hashemi J, Masjedizadeh R, Shayesteh AA, Idani E, Rajabi T. Seroepidemiology of hepatitis C and its risk factors in Khuzestan Province, South-West of Iran: A case-control study. World J Gastroenterol 2006; 12(30): 4884-4887 [PMID: 16937474 DOI: 10.3748/wjg.v12.i30.4884] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
25 Moriyama M, Arakawa Y. Treatment of interferon-α for chronic hepatitis C. Expert Opinion on Pharmacotherapy 2006;7:1163-79. [DOI: 10.1517/14656566.7.9.1163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
26 Bialek SR, Terrault NA. The Changing Epidemiology and Natural History of Hepatitis C Virus Infection. Clinics in Liver Disease 2006;10:697-715. [DOI: 10.1016/j.cld.2006.08.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
27 Lurie Y, Landau DA, Blendis L, Baruch Y, Veitsman E, Ackermann Z, Zelber-Sagie S, Halpern Z, Oren R. Acute hepatitis C in Israel: a predominantly iatrogenic disease? J Gastroenterol Hepatol 2007;22:158-64. [PMID: 17295865 DOI: 10.1111/j.1440-1746.2006.04491.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
28 Imazeki F, Yokosuka O, Fukai K, Kawai S, Kanda T, Kojima H, Saisho H. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int. 2005;25:772-778. [PMID: 15998428 DOI: 10.1111/j.1478-3231.2005.01062.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
29 Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998;28:1702-6. [DOI: 10.1002/hep.510280634] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
30 Harder J, Walter E, Riecken B, Ihling C, Bauer T. Hepatitis C virus infection in intravenous drug users. Clinical Microbiology and Infection 2004;10:768-70. [DOI: 10.1111/j.1469-0691.2004.00934.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
31 Ahmed A, Keeffe EB. Hepatitis C virus and liver transplantation. Clin Liver Dis. 2001;5:1073-1090. [PMID: 11685796 DOI: 10.1016/s1089-3261(05)70210-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
32 Chitturi S, George J. Predictors of liver-related complications in patients with chronic hepatitis C. Ann Med 2000;32:588-91. [PMID: 11209965 DOI: 10.3109/07853890009002028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
33 Mair RD, Valenzuela A, Ha NB, Ayoub WS, Daugherty T, Lutchman GA, Garcia G, Ahmed A, Nguyen MH. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol 2012;10:1412-7. [PMID: 22902757 DOI: 10.1016/j.cgh.2012.08.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
34 Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C, Vlahov D, Strathdee SA, Boitnott J, Nelson KE. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology. 2002;35:1247-1255. [PMID: 11981775 DOI: 10.1053/jhep.2002.33151] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 3.0] [Reference Citation Analysis]
35 Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology. 1999;30:1307-1311. [PMID: 10534355 DOI: 10.1002/hep.510300526] [Cited by in Crossref: 94] [Cited by in F6Publishing: 94] [Article Influence: 4.1] [Reference Citation Analysis]
36 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006; 12(45): 7239-7249 [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
37 Yeh MM, Buskell ZJ, Seeff LB, Strader D, Wright EC, Goodman ZD. More severe parenchymal injury in chronic hepatitis C acquired by recent injection drug use. J Clin Gastroenterol 2005;39:722-7. [PMID: 16082284 DOI: 10.1097/01.mcg.0000173852.70419.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
38 Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46. [PMID: 12407575 DOI: 10.1053/jhep.2002.36806] [Cited by in Crossref: 127] [Cited by in F6Publishing: 444] [Article Influence: 6.4] [Reference Citation Analysis]
39 Elefsiniotis IS, Hero B, Mariolis A, Pantazis KD, Fotos NV, Ketikoglou I, Saroglou G. Serological profile of HBV infection and liver histopathology among injecting drug users with chronic HCV infection in Greece. European Journal of Internal Medicine 2005;16:496-500. [DOI: 10.1016/j.ejim.2005.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
40 Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion 2000;40:1182-91. [DOI: 10.1046/j.1537-2995.2000.40101182.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
41 Hartman C, Berkowitz D, Rimon N, Shamir R. The effect of early treatment in children with chronic hepatitis. J Pediatr Gastroenterol Nutr 2003;37:252-7. [PMID: 12960645 DOI: 10.1097/00005176-200309000-00010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
42 Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2008;23:437-444. [PMID: 17683496 DOI: 10.1111/j.1440-1746.2007.05054.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
43 Rosen HR, Martin P. Viral hepatitis in the liver transplant recipient. Infect Dis Clin North Am 2000;14:761-84. [PMID: 10987119 DOI: 10.1016/s0891-5520(05)70130-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
44 Ahmed KT, Almashhrawi AA, Ibdah JA, Tahan V. Is the 25-year hepatitis C marathon coming to an end to declare victory? World J Hepatol 2017; 9(21): 921-929 [PMID: 28824743 DOI: 10.4254/wjh.v9.i21.921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Hirsch KR, Wright TL. ?Silent killer? or benign disease? The dilemma of hepatitis C virus outcomes. Hepatology 2000;31:536-7. [DOI: 10.1002/hep.510310241] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
46 Sharma NK, Sherker AH. Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 33-70. [DOI: 10.1007/978-1-59745-565-7_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009; 15(5): 578-582 [PMID: 19195059 DOI: 10.3748/wjg.15.578] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
48 Missiha SB, Ostrowski M, Heathcote EJ. Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors. Gastroenterology 2008;134:1699-714. [DOI: 10.1053/j.gastro.2008.02.069] [Cited by in Crossref: 152] [Cited by in F6Publishing: 127] [Article Influence: 10.9] [Reference Citation Analysis]
49 Younossi ZM. Hepatitis C Infection: A Systemic Disease. Clin Liver Dis. 2017;21:449-453. [PMID: 28689584 DOI: 10.1016/j.cld.2017.03.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
50 Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227-242. [PMID: 12085369 DOI: 10.1053/jhep.2002.34734] [Cited by in Crossref: 406] [Cited by in F6Publishing: 368] [Article Influence: 20.3] [Reference Citation Analysis]
51 Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, Wiselka M, Norris S. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52:1035-40. [PMID: 12801963 DOI: 10.1136/gut.52.7.1035] [Cited by in Crossref: 180] [Cited by in F6Publishing: 170] [Article Influence: 9.5] [Reference Citation Analysis]
52 Dowling D. Mode of transmission of hepatitis C and clinical outcome correction. Hepatology 1999;29:298-298. [DOI: 10.1002/hep.510290136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
53 Hu KQ, Yang H, Lin YC, Lindsay KL, Redeker AG. Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Int J Med Sci 2004;1:92-100. [PMID: 15912201 DOI: 10.7150/ijms.1.92] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
54 Bonkovsky HL, Mehta S. Hepatitis C: A review and update. Disease-a-Month 2001;47:610-47. [DOI: 10.1016/s0011-5029(01)90007-0] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
55 Fattovich G, Schalm SW. 12 Hepatitis C and cirrhosis. Hepatitis C. Elsevier; 2000. pp. 241-63. [DOI: 10.1016/s1874-5326(00)80016-2] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
56 Renou C, Muller P, Jouve E, Bertrand JJ, Raoult A, Benderriter T, Halfon P. Revelance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus. Am J Gastroenterol. 2001;96:1657-1659. [PMID: 11374731 DOI: 10.1111/j.1572-0241.2001.03830.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
57 Pár A, Telegdy L, Dalmi L, Müller E; Hungarian Viral Hepatitis Treatment Study Group. Therapy for chronic hepatitis C. J Physiol Paris 2001;95:399-405. [PMID: 11595466 DOI: 10.1016/s0928-4257(01)00054-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
58 Serra MA, Rodríguez F, del Olmo JA, Escudero A, Rodrigo JM. Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J Viral Hepat 2003;10:183-8. [PMID: 12753336 DOI: 10.1046/j.1365-2893.2003.00372.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
59 Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol. 1998;93:2452-2456. [PMID: 9860408 DOI: 10.1111/j.1572-0241.1998.00703.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 3.3] [Reference Citation Analysis]
60 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74-S83. [PMID: 12407579 DOI: 10.1002/hep.1840360710] [Cited by in Crossref: 195] [Cited by in F6Publishing: 127] [Article Influence: 9.8] [Reference Citation Analysis]
61 Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology. 2004;127:S62-S71. [PMID: 15508105 DOI: 10.1053/j.gastro.2004.09.017] [Cited by in Crossref: 156] [Cited by in F6Publishing: 134] [Article Influence: 8.7] [Reference Citation Analysis]
62 Zhao C, Nguyen MH. Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice. J Clin Gastroenterol. 2016;50:120-133. [PMID: 26583266 DOI: 10.1097/mcg.0000000000000446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
63 Fanning L, Kenny-walsh E, Levis J, Choudhury KR, Cannon B, Sheehan M, Whelton M, Shanahan F. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study. Hepatology 2000;31:225-9. [DOI: 10.1002/hep.510310133] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
64 Zellos A, Thomas DL, Mocilnikar C, Perlman EJ, Boitnott JK, Casella JF, Schwarz KB. High Viral Load and Mild Liver Injury in Children with Hemophilia Compared with Other Children with Chronic Hepatitis C Virus Infection: . Journal of Pediatric Gastroenterology & Nutrition 1999;29:418-23. [DOI: 10.1097/00005176-199910000-00009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
65 Florese RH, Nagano-Fujii M, Iwanaga Y, Hidajat R, Hotta H. Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res. 2002;90:119-131. [PMID: 12457968 DOI: 10.1016/s0168-1702(02)00146-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
66 Yan M, Yang J, Sun Q, Liu C, Wang Y, Wang W. Hepatocellular carcinoma that arose from primary Sjögren’s syndrome. Annals of Hepatology 2013;12:824-9. [DOI: 10.1016/s1665-2681(19)31327-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
67 Gordon SC, Lamerato LE, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale E, Xu F, Boscarino JA, Vijayadeva V, Schmidt MA, Oja-Tebbe N, Lu M. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol 2015;110:1169-77; quiz 1178. [PMID: 26215529 DOI: 10.1038/ajg.2015.203] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
68 Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003;9:S10-3. [PMID: 14586889 DOI: 10.1053/jlts.2003.50244] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 5.4] [Reference Citation Analysis]
69 Sherlock S. The hepatic flaviviridae: summary. J Viral Hepat 1999;6 Suppl 1:1-5. [PMID: 10760028 DOI: 10.1046/j.1365-2893.1999.00007.x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
70 Elefsiniotis IS, Pantazis KD, Ketikoglou ID, Koutsounas SI, Tsianos EV. Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy: . European Journal of Gastroenterology & Hepatology. [DOI: 10.1097/01.meg.0000236888.51838.36] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
71 Zheng Y, Ye LB, Liu J, Jing W, Timani KA, Yang XJ, Yang F, Wang W, Gao B, Wu ZH. Gene expression profiles of HeLa Cells impacted by hepatitis C virus non-structural protein NS4B. J Biochem Mol Biol 2005;38:151-60. [PMID: 15826491 DOI: 10.5483/bmbrep.2005.38.2.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
72 Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 2016;65:S109-19. [DOI: 10.1016/j.jhep.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
73 Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E. Which patients with hepatitis C develop liver complications? Hepatology. 2000;31:513-520. [PMID: 10655279 DOI: 10.1002/hep.510310236] [Cited by in Crossref: 110] [Cited by in F6Publishing: 115] [Article Influence: 5.0] [Reference Citation Analysis]
74 Mahajan R, Midha V, Goyal O, Mehta V, Narang V, Kaur K, Singh A, Singh D, Bhanot R, Sood A. Clinical profile of hepatitis C virus infection in a developing country: India. J Gastroenterol Hepatol 2018;33:926-33. [PMID: 28921677 DOI: 10.1111/jgh.13995] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
75 Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E; European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886-2895. [PMID: 12425564 DOI: 10.1111/j.1572-0241.2002.07057.x] [Cited by in Crossref: 219] [Cited by in F6Publishing: 219] [Article Influence: 11.0] [Reference Citation Analysis]
76 Bonkovsky HL, Mehta S. Hepatitis C: A review and update. Journal of the American Academy of Dermatology 2001;44:159-82. [DOI: 10.1067/mjd.2001.109311] [Cited by in Crossref: 70] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
77 Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002;17:423-30. [PMID: 11982723 DOI: 10.1046/j.1440-1746.2002.02730.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 3.6] [Reference Citation Analysis]
78 Patel H, Heathcote EJ. When to treat and the benefits of treating hepatitis C in patients with haemophilia. Haemophilia 2009;15:20-32. [DOI: 10.1111/j.1365-2516.2008.01917.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
79 Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65. [PMID: 30791221 DOI: 10.1002/cam4.1998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
80 Tokunaga M, Uto H, Oda K, Tokunaga M, Mawatari S, Kumagai K, Haraguchi K, Oketani M, Ido A, Ohnou N, Utsunomiya A, Tsubouchi H. Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Gastroenterol 2014;49:1567-77. [DOI: 10.1007/s00535-013-0928-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]